US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings
Middlemen Markups Are Costing Patients At The Pharmacy Counter
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.
